Advanced Member
Posted 09 September 2010 - 01:49 PM
Does Ariad treat all bcr-abl mutations or only the T315i ?
I get the impression from reading that it is the most potent of all the drugs and has been able to drive MMR in only several months. I wonder if it would work better than Tasigna/Sprycell?
May have to wait until the next ASCO meeting for results to be announced.
Diagnosed 11 May 2011 (100% FiSH, 155% PCR)
with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein
Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate
6-8 grams Curcumin C3 complex.
2015 PCR: < 0.01% (M.D. Anderson scale)
2016 PCR: < 0.01% (M.D. Anderson scale)
March 2017 PCR: 0.01% (M.D. Anderson scale)
June 2017 PCR: "undetected"
September 2017 PCR: "undetected"
Advanced Member
Posted 09 September 2010 - 01:57 PM
From Ariad's website.
"The primary target for AP24534 is BCR-ABL"
http://www.ariad.com/wt/tertiarypage/AP24534
New Member
Posted 10 September 2010 - 12:51 PM
They showed in a white paper that it treats all known mutations, and in many cases compound mutations. That is where you could have a double mutation on the same DNA strand. There were a couple of compound mutations that it had problems with and required very high dosages, more than what is currently the standard dosage, but I asked my onc about that once and he explained that that case may be academic in that there may be a natural destruction of those cells since the double mutation may interefere with normal cell division. But it was interesting.
What I think is becoming the biggest need right now, is to find an answer for those who don't respond, yet have no known mutations. I sure hope there is research to better understand why or why not a patient responds, and help target the treatment with known data rather than try something and see if it works.
Hans
0 members, 1 guests, 0 anonymous users
